AI assistant
Sending…
Processa Pharmaceuticals, Inc. — Director's Dealing 2025
Jul 28, 2025
35172_dirs_2025-07-28_2383c80d-d12c-46b3-92b9-b0998cc5d9db.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2025-07-28
Reporting Person: Guy Wendy (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-07-24 | Restricted Stock Units | $0 | A | 1366046 | Acquired | Common Stock (1366046) | Direct |
Footnotes
F1: Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ("Omnibus Plan"), of which 1,349,245 shares are subject to stockholder approval of the revised Omnibus Plan.
F2: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028.
More from Processa Pharmaceuticals, Inc.
Regulatory Filings
2026
Feb 19
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Regulatory Filings
2026
Jan 7
Regulatory Filings
2025
Dec 15
Major Shareholding Notification
2025
Nov 7
Interim / Quarterly Report
2025
Nov 6
Major Shareholding Notification
2025
Oct 15